Alembic Pharmaceuticals’ 100% subsidiary Alembic Global Holding has entered into joint venture (JV) deal with Adwiya Mami SARL Algeria. The deal envisages investment by AGH to the extent of 49% equity of Adwiya Mami. Post conclusion of deal the company will be renames as Alembic Mami SPA.
Adwiya Mami owns a state of art formulation plant with a capacity of 1.2 billion per annum oral solids. The plant has been designed and developed by a leading European Pharmaceutical company in line with the cGMP requirements. The plant has enough headroom for future expansion. The investment in Adwiya Mami will give AGH a quick entry to the attractive Algerian market.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
